| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Original Articles |
Inhaled nitric oxide (NO) causes selective pulmonary vasodilation and improves gas exchange in acute lung failure. In experimental pulmonary hypertension, we compared the influence of the aerosolized vasodilatory prostaglandins (PG) PGI2 and PGE1 on vascular tone and gas exchange to that of infused prostanoids (PGI2, PGE1) and inhaled NO. An increase of pulmonary artery pressure (Ppa) from 8 to approximately 34 mmHg was provoked by continuous infusion of U-46619 (thromboxane A2 (TxA2) analogue) in blood-free perfused rabbit lungs. This was accompanied by formation of moderate lung oedema and severe ventilation-perfusion (V'/Q') mismatch, with predominance of shunt flow (>50%, assessed by the multiple inert gas elimination technique). When standardized to reduce the Pps by approximately 10 mmHg, inhaled NO (200 ppm), aerosolized PGI2 (4 ng x kg(-1) x min(-1)) and nebulized PGE1 (8 ng x kg(-1) x min(-1)) all reduced both pre- and postcapillary vascular resistance, but did not affect formation of lung oedema. All inhalative agents improved the V'/Q' mismatch and reduced shunt flow, the rank order of this capacity being NO > PGI2 > PGE1. In contrast, lowering of Ppa by intravascular administration of PGI2 and PGE1 did not improve gas exchange. "Supratherapeutic" doses of inhaled vasodilators in control lungs (400 ppm NO, 30 ng x kg(-1) x min(-1) of PGI2 or PGE1) did not provoke vascular leakage or affect the physiological V'/Q' matching. We conclude that aerosolization of prostaglandins I2 and E1 is as effective as inhalation of nitric oxide in relieving pulmonary hypertension. When administered via this route instead of being infused intravascularly, the prostanoids are capable of improving ventilation-perfusion matching, suggesting selective vasodilation in well-ventilated lung areas.
This article has been cited by other articles:
|
|
 |
|
  H. H. Leuchte, T. Meis, M. El-Nounou, J. Michalek, and J. Behr Inhalation of endothelin receptor blockers in pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, April 1, 2008; 294(4): L772 - L777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Goyal, U. Kiran, S. Chauhan, R. Juneja, and M. Choudhary Efficacy of nitroglycerin inhalation in reducing pulmonary arterial hypertension in children with congenital heart disease Br. J. Anaesth., August 1, 2006; 97(2): 208 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.T. Schermuly, H. Leuchte, H.A. Ghofrani, N. Weissmann, F. Rose, M. Kohstall, H. Olschewski, C. Schudt, F. Grimminger, W. Seeger, et al. Zardaverine and aerosolised iloprost in a model of acute respiratoryfailure Eur. Respir. J., August 1, 2003; 22(2): 342 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Schermuly, A. Roehl, N. Weissmann, H. A. Ghofrani, H. Leuchte, F. Grimminger, W. Seeger, and D. Walmrath Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, December 1, 2001; 281(6): L1361 - L1368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hache, A. Y. Denault, S. Belisle, P. Couture, D. Babin, F. Tetrault, and J.-G. Guimond Inhaled prostacyclin (PGI2) is an effective addition to the treatment of pulmonary hypertension and hypoxia in the operating room and intensive care unit : [L'inhalation de prostacycline (PGI2) est un traitement complementaire efficace de l'hypertension pulmonaire et de l'hypoxie observees en salle d'operation et a l'unite des soins intensifs] Can J Anesth, October 1, 2001; 48(9): 924 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Stuesse, G. D. Giraud, A. A. Vlessis, A. Starr, and D. D. Trunkey Hemodynamic effects of S-nitrosocysteine, an intravenous regional vasodilator J. Thorac. Cardiovasc. Surg., August 1, 2001; 122(2): 371 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Schermuly, N. Weissmann, B. Enke, H. A. Ghofrani, W. G. Forssmann, F. Grimminger, W. Seeger, and D. Walmrath Urodilatin, a Natriuretic Peptide Stimulating Particulate Guanylate Cyclase, and the Phosphodiesterase 5 Inhibitor Dipyridamole Attenuate Experimental Pulmonary Hypertension . Synergism upon Coapplication Am. J. Respir. Cell Mol. Biol., August 1, 2001; 25(2): 219 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Maurenbrecher, M. Lamy, G. Deby-Dupont, P. Frascarolo, and G. Hedenstierna An Animal Model of Response and Nonresponse to Inhaled Nitric Oxide in Endotoxin-Induced Lung Injury Chest, August 1, 2001; 120(2): 573 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Schutte, A. Lockinger, W. Seeger, and F. Grimminger Aerosolized PGE1, PGI2 and nitroprusside protect against vascular leakage in lung ischaemia-reperfusion Eur. Respir. J., July 1, 2001; 18(1): 15 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Schenk, V. Petkov, C. Madl, L. Kramer, M. Kneussl, R. Ziesche, and I. Lang Aerosolized Iloprost Therapy Could Not Replace Long-term IV Epoprostenol (Prostacyclin) Administration in Severe Pulmonary Hypertension Chest, January 1, 2001; 119(1): 296 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Schroeder, G. L. Wood, J. S. Plotkin, and P. C. Kuo Intraoperative Use of Inhaled PGI2 for Acute Pulmonary Hypertension and Right Ventricular Failure Anesth. Analg., August 1, 2000; 91(2): 291 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Schermuly, A. Roehl, N. Weissmann, H. A. Ghofrani, C. Schudt, H. Tenor, F. Grimminger, W. Seeger, and D. Walmrath Subthreshold Doses of Specific Phosphodiesterase Type 3 and 4 Inhibitors Enhance the Pulmonary Vasodilatory Response to Nebulized Prostacyclin with Improvement in Gas Exchange J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 512 - 520. [Abstract] [Full Text]
|
|
|
|
 |
|
 A J Peacock Rare diseases bullet 5: Primary pulmonary hypertension Thorax, December 1, 1999; 54(12): 1107 - 1118. [Full Text]
|
|
|
|
 |
|
 R. T. SCHERMULY, H. A. GHOFRANI, B. ENKE, N. WEISSMANN, F. GRIMMINGER, W. SEEGER, C. SCHUDT, and D. WALMRATH Low-dose Systemic Phosphodiesterase Inhibitors Amplify the Pulmonary Vasodilatory Response to Inhaled Prostacyclin in Experimental Pulmonary Hypertension Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): 1500 - 1506. [Abstract] [Full Text]
|
|
|
|
|
|
G. HERMLE, H. SCHÜTTE, D. WALMRATH, K. GEIGER, W. SEEGER, and F. GRIMMINGER Ventilation-Perfusion Mismatch after Lung Ischemia-Reperfusion . Protective Effect of Nitric Oxide Am. J. Respir. Crit. Care Med., October 1, 1999; 160(4): 1179 - 1187. [Abstract] [Full Text]
|
|
|
|
|
|
M. Aranda, K. K. Bradford, and R. G. Pearl Combined Therapy with Inhaled Nitric Oxide and Intravenous Vasodilators During Acute and Chronic Experimental Pulmonary Hypertension Anesth. Analg., July 1, 1999; 89(1): 152 - 152. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
